John Leonard, Intellia Therapeutics CEO

In­tel­lia gets FDA clear­ance to start hered­i­tary an­gioede­ma gene edit­ing tri­al in US

In­tel­lia Ther­a­peu­tics an­nounced Thurs­day morn­ing that the FDA cleared it to test a gene edit­ing ther­a­py for hered­i­tary an­gioede­ma (HAE) in clin­i­cal tri­als in the US. The Cam­bridge, MA biotech is al­ready run­ning the tri­al in New Zealand, the Nether­lands, and the UK.

In­tel­lia’s HAE treat­ment, known as NT­LA-2002, is the first in vi­vo gene edit­ing treat­ment de­liv­ered by lipid nanopar­ti­cles to get cleared by the FDA for hu­man tri­als. Lipid nanopar­ti­cles, or LNPs, are tiny balls of fat­ty acids that were used as de­liv­ery ve­hi­cles in the mR­NA Covid vac­cines.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.